

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				C m p l e t e d i f K n o w n	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/531,969
				Filing Date	March 21, 2000
				First Named Inventor	Jan Geliebter
				Art Unit	1632
				Examiner Name	Peter Paras, Jr.
				Attorney Docket Number	96700/596
Sheet	1	of	2		

MAY 23 2003

RECEIVED

[illegible][illegible]

Examiner Signature	<i>Pete Parnas</i>	Date Considered	8/5/03
-----------------------	--------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Required to respond to a collection of information unless it contains a valid OMB

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Application Number	09/531,969
Filing Date	March 21, 2000
First Named Inventor	Jan Geliebter
Group Art Unit	1632
Examiner Name	Peter Paras, Jr.
Attorney Docket Number	96700/596

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T ²
	3 ✓	Channon, Keith M., et al., Adenoviral gene transfer of nitric oxide synthase: High level expression in human vascular cells, Cardiovascular Research 32 (1996) 962-972	
	4 ✓	Fan, SF et al. BIOSIS Accession No. PREV199598178283, An analysis of the maxi-K+ (K-CA) channel in cultured human corporal smooth muscle cells. J. Urology 153: 818-825, 1995 [Abstract Only]	
	5 ✓	Bredt, David S, Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase, Nature 351 (1991) 714-718	
	6 ✓	Magee, T et al. Cloning of a Novel Neuronal Nitric Oxide Synthase Expressed in Penis and Lower Uninary Tract, Biochemical Biophysical Res. Commun. 226 (1996) 145-151	
	7 ✓	Kim, Young Chan et al. CA Accession No. 122:77664 HCA, Experimental evidence for endothelium dependent relaxation and neuronal nitric oxide in corpus cavernosum, Yonsei Medical Journal 35(3): 308-13, 1994 [Abstract only]	
	8 ✓	Mills, TM et al. MEDLINE Accession No. NLM8735191, Sites of androgenic regulation of cavernosal blood pressure during penile erection in the rat, International Journal of Impotence Research 8: 29-34,1996 [Abstract Only]	
	9 ✓	Christ, GJ et al. MEDLINE Accession No. NLM7688635, The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle, Intern. J. Impotence Res. 5: 77-93, 1993 [Abstract Only]	
	10 ✓	Melman, A et al. The Successful Long-Term Treatment of Age Related Erectile Dysfunction with HSLO CDNA in Rats in Vivo, The Journal of Urology, Vol. 170, July 2003 (In Press)	

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MAY 23 2003

RECEIVED